Experienced in Bladder Cancer

Dr. Richard Lauer

Hematology
Office
Albuquerque, NM 
Experienced in Bladder Cancer
Office
Albuquerque, NM 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Richard Lauer is a Hematologist in Albuquerque, New Mexico. Dr. Lauer is rated as an Experienced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Multiple Myeloma, and Prostate Cancer.

His clinical research consists of co-authoring 11 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 2 clinical trials in the study of Bladder Cancer.

Specialties
Hematology
Licenses
Internal Medicine in NM
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Office
Albuquerque, NM 87102
Other Locations
University of New Mexico Medical Group Inc
933 Bradbury Dr SE Ste 2222, Albuquerque, NM 87106

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Completed
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188
Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188
Enrollment Status: Completed
Publish Date: March 18, 2025
Intervention Type: Drug, Procedure
Study Drugs: Pembrolizumab, Gemcitabine, Cisplatin
Study Phase: Phase 1/Phase 2
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Procedure, Drug
Study Drugs: Cabozantinib S-Malate, Crizotinib, Savolitinib, Sunitinib Malate
Study Phase: Phase 2
A Randomized, Double-blinded, Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer: Hoosier Cancer Research Network GU14-182
A Randomized, Double-blinded, Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer: Hoosier Cancer Research Network GU14-182
Enrollment Status: Completed
Publish Date: September 30, 2022
Intervention Type: Other, Drug
Study Phase: Phase 2
A Phase 2 Open-label Study to Evaluate the Efficacy and Safety of Seviteronel in Subjects With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
A Phase 2 Open-label Study to Evaluate the Efficacy and Safety of Seviteronel in Subjects With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
Enrollment Status: Completed
Publish Date: February 01, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

11 Total Publications

Dysregulation of the PRUNE2/PCA3 genetic axis in human prostate cancer: from experimental discovery to validation in two independent patient cohorts.
Dysregulation of the PRUNE2/PCA3 genetic axis in human prostate cancer: from experimental discovery to validation in two independent patient cohorts.
Journal: eLife
Published: July 16, 2022
Similar Doctors
Experienced in Bladder Cancer
Dr. Ian Rabinowitz
Hematology
Experienced in Bladder Cancer
Dr. Ian Rabinowitz
Hematology

UNM Medical Group Inc

Albuquerque, NM 
 (2.2 miles away)
505-272-4946
Languages Spoken:
English
See accepted insurances

Ian Rabinowitz is a Hematologist in Albuquerque, New Mexico. Dr. Rabinowitz is rated as a Distinguished provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Embryonal Tumor with Multilayered Rosettes, Ependymoma, Atypical Teratoid Rhabdoid Tumor (ATRT), and Neuroepithelioma.

Experienced in Bladder Cancer
Dr. Ethan Binder
Hematology
Experienced in Bladder Cancer
Dr. Ethan Binder
Hematology

Presbyterian Rust Medical Center

2400 Unser Blvd SE, 
Rio Rancho, NM 
 (11.9 miles away)
505-559-6100
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ethan Binder is a Hematologist in Rio Rancho, New Mexico. Dr. Binder is rated as an Advanced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Choriocarcinoma, Pleuropulmonary Blastoma, Paget Disease of the Breast, and Breast Cancer.

Experienced in Bladder Cancer
Dr. Farrukh Ashraf
Hematology
Experienced in Bladder Cancer
Dr. Farrukh Ashraf
Hematology

Presbyterian Rust Medical Center

2400 Unser Blvd SE, 
Rio Rancho, NM 
 (11.9 miles away)
505-559-6100
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Farrukh Ashraf is a Hematologist in Rio Rancho, New Mexico. Dr. Ashraf is rated as a Distinguished provider by MediFind in the treatment of Bladder Cancer. Her top areas of expertise are Neuroendocrine Tumor, Thrombocytopenia, Anemia, and Childhood Iron Deficiency Anemia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lauer's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 105 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile